Stoke Therapeutics, Inc. (STOK) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $6.00K; Additional Paid in CapitalUSD $955.42M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-542.00K; Retained Earnings (Accumulated Deficit)USD $-609.34M.
- 2026-03-31: Common Stock, Value, IssuedUSD $6.00K; Additional Paid in CapitalUSD $942.70M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-115.00K; Retained Earnings (Accumulated Deficit)USD $-547.72M.
- 2025-12-31: Common Stock, Value, IssuedUSD $5.00K; Additional Paid in CapitalUSD $849.62M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $543.00K; Retained Earnings (Accumulated Deficit)USD $-497.71M.
- 2025-09-30: Common Stock, Value, IssuedUSD $5.00K; Additional Paid in CapitalUSD $747.43M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $446.00K; Retained Earnings (Accumulated Deficit)USD $-439.78M.
Stoke Therapeutics, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $6.00K | $955.42M | $-542.00K | $-609.34M | $345.55M | 3 month · $10.80M | (m) |
| 2026-03-31 | $6.00K | $942.70M | $-115.00K | $-547.72M | $394.88M | 3 month · $8.75M | (m) |
| 2025-12-31 | $5.00K | $849.62M | $543.00K | $-497.71M | $352.46M | 12 month · $32.24M | (m) |
| 2025-09-30 | $5.00K | $747.43M | $446.00K | $-439.78M | $308.11M | 3 month · $8.04M | (m) |
| 2025-06-30 | $5.00K | $736.28M | $96.00K | $-401.43M | $334.94M | 3 month · $7.60M | (m) |
| 2025-03-31 | $5.00K | $728.12M | $-104.00K | $-377.95M | $350.07M | 3 month · $6.75M | (m) |
| 2024-12-31 | $5.00K | $720.00M | $-151.00K | $-490.83M | $229.02M | 12 month · $27.47M | (m) |
| 2024-09-30 | $5.00K | $712.29M | $166.00K | $-480.35M | $232.11M | 3 month · $7.49M | (m) |
| 2024-06-30 | $5.00K | $696.64M | $-15.00K | $-453.92M | $242.71M | 3 month · $7.43M | (m) |
| 2024-03-31 | $5.00K | $568.56M | (m) | $-428.22M | $140.34M | 3 month · $5.41M | (m) |
| 2023-12-31 | $5.00K | $561.43M | $-24.00K | $-401.85M | $159.56M | 12 month · $25.26M | (m) |
| 2023-09-30 | $4.00K | $548.03M | $-147.00K | $-374.89M | $173.00M | 3 month · $6.55M | (m) |
| 2023-06-30 | $4.00K | $540.92M | $-379.00K | $-350.35M | $190.19M | 3 month · $6.76M | (m) |
| 2023-03-31 | $4.00K | $534.11M | $-598.00K | $-319.69M | $213.82M | 3 month · $5.89M | (m) |
| 2022-12-31 | $4.00K | $483.17M | $-1.18M | $-297.15M | $184.85M | 12 month · $22.85M | (m) |
| 2022-09-30 | $4.00K | $477.34M | $-1.70M | $-271.50M | $204.14M | 3 month · $5.93M | (m) |
| 2022-06-30 | $4.00K | $470.98M | $-1.28M | $-245.38M | $224.32M | 3 month · $6.16M | (m) |
| 2022-03-31 | $4.00K | $461.39M | $-684.00K | $-220.73M | $239.98M | 3 month · $4.97M | (m) |
| 2021-12-31 | $4.00K | $414.02M | $-168.00K | $-196.08M | $217.78M | 12 month · $16.45M | (m) |
| 2021-09-30 | $4.00K | $409.17M | $-22.00K | $-171.63M | $237.51M | 3 month · $4.61M | (m) |
| 2021-06-30 | $4.00K | $404.14M | $-42.00K | $-149.04M | $255.07M | 3 month · $4.45M | (m) |
| 2021-03-31 | $4.00K | $399.53M | (m) | $-127.07M | $272.46M | 3 month · $2.70M | (m) |
| 2020-12-31 | $4.00K | $396.35M | (m) | $-110.28M | $286.08M | 12 month · $5.77M | (m) |
| 2020-09-30 | $3.00K | $288.25M | (m) | $-95.72M | $192.53M | 3 month · $1.78M | (m) |
| 2020-06-30 | $3.00K | $285.43M | (m) | $-82.03M | $203.40M | 3 month · $1.65M | (m) |
| 2020-03-31 | $3.00K | $283.41M | (m) | $-69.07M | $214.34M | 3 month · $754.00K | (m) |
| 2019-12-31 | $3.00K | $282.46M | (m) | $-58.03M | $224.43M | 12 month · $1.92M | (m) |
| 2019-09-30 | $3.00K | $281.56M | (m) | $-47.88M | $233.68M | 3 month · $731.00K | (m) |
| 2019-06-30 | $3.00K | $280.80M | (m) | $-39.27M | $241.54M | 3 month · $298.00K | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | $99.58M | 3 month · $181.00K | (m) |
| 2018-12-31 | (m) | $130.78M | (m) | $-25.71M | $105.07M | 12 month · $240.00K | 12 month · $378.00K |
| 2018-09-30 | (m) | (m) | (m) | (m) | $19.39M | 3 month · $40.00K | 3 month · $32.00K |
| 2018-06-30 | (m) | (m) | (m) | (m) | $9.29M | 3 month · $77.00K | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | $12.22M | 3 month · $4.00K | 3 month · $88.00K |
| 2017-12-31 | (m) | (m) | (m) | (m) | $-1.29M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |